Bachem Holding AG, a leading biochemical company, represents a set of core values and a strong corporate philosophy. It prioritizes innovation, quality, and customer satisfaction in its operations. Bachem values continuous improvement and invests in research and development to stay at the forefront of technological advancements. The company's philosophy is centered on providing high-quality products and services to support the development of innovative pharmaceuticals and diagnostics. Bachem is committed to fostering long-term partnerships with its customers, while promoting sustainability and ethical business practices. Through its dedication to excellence, Bachem Holding AG has established itself as a trusted partner in the pharmaceutical industry.

Bachem Holding AG, a leading biochemical company, is primarily present in several countries and regions worldwide. With its headquarters in Switzerland, Bachem has a strong presence in European countries such as Germany, the United Kingdom, France, and Italy. The company also operates in North America, with facilities in the United States and Canada. Furthermore, Bachem has expanded its reach to key markets in Asia, including China and Japan, as well as other regions globally. As a result, Bachem Holding AG has established a robust international presence, enabling it to serve a diverse range of markets with its high-quality biochemical products and services.

Bachem Holding AG, a renowned pharmaceutical company, has achieved noteworthy milestones over the years. With their commitment to innovation and excellence, Bachem has successfully expanded its global presence and diversified its product portfolio. One key milestone includes the company's establishment in 1971, laying the foundation for its success in peptide research and manufacturing. Bachem has also achieved significant advancements in peptide synthesis technology, enabling efficient and scalable production processes. Moreover, the company has consistently forged strategic partnerships and collaborations with industry leaders to enhance its research capabilities and market reach. These milestones demonstrate Bachem Holding AG's dedication to delivering high-quality products and solutions to the pharmaceutical industry, solidifying its position as a leading player in the market.

Bachem Holding AG is a renowned global provider of peptide-based products and services for the pharmaceutical and biotechnology industries. Established in 1971, the company has a rich history of expertise in the field of peptides. Bachem specializes in the production of high-quality peptides, complex organic molecules, and innovative biochemicals. With a presence in Europe, the United States, and Asia, Bachem caters to a diverse range of customers worldwide. The company's commitment to innovation, quality, and customer satisfaction has made it a trusted partner in the pharmaceutical industry. Bachem Holding AG continues to drive advancements in peptide technology, contributing significantly to the development of life-saving drugs.

The main competitors of Bachem Holding AG in the market include other prominent players in the pharmaceutical and life sciences industry. Some of the key competitors include Lonza Group Ltd, Merck KGaA, and Catalent, Inc. These companies often operate in similar therapeutic areas and offer a range of services and products that may compete with Bachem's offerings. Bachem Holding AG, being a leading provider of peptide-based pharmaceuticals, custom synthesis, and manufacturing, faces competition from these and several other global and regional companies in the market.

Bachem Holding AG primarily operates in the pharmaceutical industry.

Bachem Holding AG operates as a leading supplier of peptide-based active pharmaceutical ingredients (APIs) and innovative biochemicals for the pharmaceutical and biotechnology industries worldwide. The company specializes in the development, manufacturing, and marketing of a vast range of peptide-based products, including generic peptides, cosmetic peptides, and custom synthesis peptides. With a strong focus on research and development, Bachem aims to provide high-quality, reliable, and customized solutions to support the success and advancements of its customers in the pharmaceutical sector. Bachem Holding AG remains committed to delivering innovative peptide-based solutions and driving progress in the healthcare industry.

The Bachem Holding P/E ratio is 47.57.

The Bachem Holding P/S ratio is 8.96.

The Quality Investing for Bachem Holding is 8/10.

The expected Bachem Holding revenue is 628.18 M CHF.

The expected Bachem Holding profit is 118.39 M CHF.

The English translation of the provided text is as follows: "Bachem Holding AG is a leading manufacturer of peptides and specialized chemicals for the pharmaceutical industry. The company operates globally and is headquartered in Switzerland. Bachem's business model is based on two pillars: the production and sale of innovative peptides and specialized chemicals. Bachem offers a wide range of products and services to support its customers' research and development activities. These include customized syntheses, GMP-grade peptides, and specialized compounds for clinical research. A key factor in the company's success is the high quality of its products and services. Bachem has state-of-the-art technologies and processes to serve its customers. The company invests continuously in research and development to find innovative solutions that meet market needs. Bachem operates in three business areas. The first area is peptides and amino acids. Here, Bachem develops and produces peptides for the biopharmaceutical industry and academic research. The second business area is the sale of specialized chemicals. Bachem offers a wide range of intermediates and reagents used in the pharmaceutical industry and other sectors. The third area is the manufacture of peptide drug candidates (APIs). Here, Bachem provides GMP production and clinical development services to its customers. As a global company, Bachem has offices and sales offices in Europe, North America, and Asia. The company is active in markets such as pharmaceuticals, biotechnology, diagnostics, cosmetics, and animal health. Bachem's customers include renowned pharmaceutical and biotech companies, academic institutions, and CROs. Bachem aims to further penetrate the market for peptides and specialized chemicals and diversify its business. The company works closely with its customers to develop innovative products and solutions that are a result of their growing trust and longstanding relationship with Bachem. In summary, Bachem Holding AG's business model focuses on the production and sale of peptides and specialized chemicals for the pharmaceutical and biotechnology industry. Bachem offers a wide range of products and top-notch customer service to meet its customers' needs. The company operates globally and aims to continue growing and diversifying in the market for peptides and specialized chemicals."

Bachem Holding pays a dividend of 0.35 CHF distributed over 1 payouts per year.

Bachem Holding pays out a dividend 1 times a year.

The ISIN of Bachem Holding is CH0012530207.

The WKN of Bachem Holding is 914589.

The ticker of Bachem Holding is BANB.SW.

Over the past 12 months, Bachem Holding paid a dividend of 0.37 CHF . This corresponds to a dividend yield of about 0.49 %. For the coming 12 months, Bachem Holding is expected to pay a dividend of 0.39 CHF.

The current dividend yield of Bachem Holding is 0.49 %.

Bachem Holding pays a quarterly dividend. This is distributed in the months of May, May, May, May.

Bachem Holding paid dividends every year for the past 26 years.

For the upcoming 12 months, dividends amounting to 0.39 CHF are expected. This corresponds to a dividend yield of 0.52 %.

Bachem Holding is assigned to the 'Health' sector.

To receive the latest dividend of Bachem Holding from 4/30/2024 amounting to 0.4 CHF, you needed to have the stock in your portfolio before the ex-date on 4/26/2024.

The last dividend was paid out on 4/30/2024.

In the year 2023, Bachem Holding distributed 0.35 CHF as dividends.

The dividends of Bachem Holding are distributed in CHF.